Integrating heterogeneous data to facilitate COVID-19 drug repurposing

In the COVID-19 pandemic, drug repositioning has presented itself as an alternative to the time-consuming process of generating new drugs. This review describes a drug repurposing process that is based on a new data-driven approach: we put forward five information paths that associate COVID-19-relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Prieto Santamaría, Lucía, Díaz Uzquiano, Marina, Ugarte Carro, Esther, Ortiz-Roldán, Nieves, Pérez Gallardo, Yuliana, Rodríguez-González, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2022
Materias:
Post-Screen (Grey)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520166/
https://www.ncbi.nlm.nih.gov/pubmed/34666181
http://dx.doi.org/10.1016/j.drudis.2021.10.002
_version_ 1784584610386018304
author Prieto Santamaría, Lucía
Díaz Uzquiano, Marina
Ugarte Carro, Esther
Ortiz-Roldán, Nieves
Pérez Gallardo, Yuliana
Rodríguez-González, Alejandro
author_facet Prieto Santamaría, Lucía
Díaz Uzquiano, Marina
Ugarte Carro, Esther
Ortiz-Roldán, Nieves
Pérez Gallardo, Yuliana
Rodríguez-González, Alejandro
author_sort Prieto Santamaría, Lucía
collection PubMed
description In the COVID-19 pandemic, drug repositioning has presented itself as an alternative to the time-consuming process of generating new drugs. This review describes a drug repurposing process that is based on a new data-driven approach: we put forward five information paths that associate COVID-19-related genes and COVID-19 symptoms with drugs that directly target these gene products, that target the symptoms or that treat diseases that are symptomatically or genetically similar to COVID-19. The intersection of the five information paths results in a list of 13 drugs that we suggest as potential candidates against COVID-19. In addition, we have found information in published studies and in clinical trials that support the therapeutic potential of the drugs in our final list.
format Online
Article
Text
id pubmed-8520166
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-85201662021-10-18 Integrating heterogeneous data to facilitate COVID-19 drug repurposing Prieto Santamaría, Lucía Díaz Uzquiano, Marina Ugarte Carro, Esther Ortiz-Roldán, Nieves Pérez Gallardo, Yuliana Rodríguez-González, Alejandro Drug Discov Today Post-Screen (Grey) In the COVID-19 pandemic, drug repositioning has presented itself as an alternative to the time-consuming process of generating new drugs. This review describes a drug repurposing process that is based on a new data-driven approach: we put forward five information paths that associate COVID-19-related genes and COVID-19 symptoms with drugs that directly target these gene products, that target the symptoms or that treat diseases that are symptomatically or genetically similar to COVID-19. The intersection of the five information paths results in a list of 13 drugs that we suggest as potential candidates against COVID-19. In addition, we have found information in published studies and in clinical trials that support the therapeutic potential of the drugs in our final list. The Author(s). Published by Elsevier Ltd. 2022-02 2021-10-16 /pmc/articles/PMC8520166/ /pubmed/34666181 http://dx.doi.org/10.1016/j.drudis.2021.10.002 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Post-Screen (Grey)
Prieto Santamaría, Lucía
Díaz Uzquiano, Marina
Ugarte Carro, Esther
Ortiz-Roldán, Nieves
Pérez Gallardo, Yuliana
Rodríguez-González, Alejandro
Integrating heterogeneous data to facilitate COVID-19 drug repurposing
title Integrating heterogeneous data to facilitate COVID-19 drug repurposing
title_full Integrating heterogeneous data to facilitate COVID-19 drug repurposing
title_fullStr Integrating heterogeneous data to facilitate COVID-19 drug repurposing
title_full_unstemmed Integrating heterogeneous data to facilitate COVID-19 drug repurposing
title_short Integrating heterogeneous data to facilitate COVID-19 drug repurposing
title_sort integrating heterogeneous data to facilitate covid-19 drug repurposing
topic Post-Screen (Grey)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520166/
https://www.ncbi.nlm.nih.gov/pubmed/34666181
http://dx.doi.org/10.1016/j.drudis.2021.10.002
work_keys_str_mv AT prietosantamarialucia integratingheterogeneousdatatofacilitatecovid19drugrepurposing
AT diazuzquianomarina integratingheterogeneousdatatofacilitatecovid19drugrepurposing
AT ugartecarroesther integratingheterogeneousdatatofacilitatecovid19drugrepurposing
AT ortizroldannieves integratingheterogeneousdatatofacilitatecovid19drugrepurposing
AT perezgallardoyuliana integratingheterogeneousdatatofacilitatecovid19drugrepurposing
AT rodriguezgonzalezalejandro integratingheterogeneousdatatofacilitatecovid19drugrepurposing

Ejemplares similares